

I hereby certify that this correspondence is
being deposited via the United States
Postal Service as first class mail in an
envelope addressed to: Assistant Commissioner
for Trademarks, 2900 Crystal Drive, Arlington,
Virginia 22202-3513, on 7-16-98
FELPE & LYNCH



BOX 562/6A 1644

LUD 5253.5 DIV. - JEL/NDH

By *Fani Kostopoulou*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Thierry BOON-FALLEUR et al.

Serial No. : 08/819,669

Filed : March 17, 1997

For : TUMOR REJECTION ANTIGEN PRECURSORS, TUMOR
REJECTION ANTIGENS AND USES THEREOF

Art Unit : 1644

Examiner : T. Cunningham

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

July 6, 1998

RECEIVED

15 1998

SUPPLEMENTAL RESPONSE

SIR:

Further to their amendment of June 9, 1998, applicants ask that this application be amended as follows:

IN THE SPECIFICATION

~~Please replace the paper copy of sequence information and computer readable form thereof with the attached materials.~~

REMARKS

At page 5, point 10 of the Office Action of March 17, 1998, the Examiner stated:

"If any originally disclosed MAGE-1 amino acid sequence has been modified or corrected the applicant is requested to notify the Examiner of the correction and date the correction was made."